TB-500 vs KPV
Both compounds appear in the regeneration and inflammation research literature, but through unrelated mechanistic pathways. TB-500 has been investigated for actin-cytoskeleton modulation and cell-migration kinetics. KPV is a melanocortin-derived tripeptide studied for NF-κB-pathway modulation and intestinal inflammation endpoints. This page summarises how the published research separates them.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | 17-residue synthetic fragment corresponding to the active region of thymosin β4 | Tripeptide (Lys-Pro-Val) derived from the C-terminal region of α-melanocyte-stimulating hormone (α-MSH) |
| Approximate molecular weight | 1888.2 g/mol | 342.4 g/mol |
| Best-studied mechanism | G-actin sequestration via conserved actin-binding motif; cell-migration kinetics modulation | NF-κB pathway inhibition; PepT1-mediated intestinal uptake |
| Primary tissues in published literature | Cardiac tissue, corneal epithelium, vascular endothelium, dermal wound bed | Intestinal epithelium, colonic mucosa, skin inflammation models |
| Common research administration routes | Intramuscular and subcutaneous in rodent and equine studies | Intraperitoneal, oral (PepT1-mediated), and topical in rodent models |
| Reconstitution practice | Bacteriostatic water; lyophilised vial format | Bacteriostatic water; lyophilised vial format |
| Ronin catalog vial size | 10 mg lyophilised | 10 mg lyophilised |
How they differ in mechanism
TB-500 corresponds to the active region of thymosin β4 and has been investigated primarily through the actin-binding lens. The conserved Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln motif binds monomeric G-actin in 1:1 stoichiometry, modulating the equilibrium between G-actin and F-actin filaments. Downstream, the published literature reports altered cell-migration kinetics across endothelial, epithelial, and cardiac cell types and changes in integrin-linked kinase activation.
KPV is a tripeptide derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone. The published mechanistic work describes inhibition of the NF-κB inflammatory pathway, with functional uptake through the PepT1 transporter in intestinal epithelial cells (Dalmasso et al., Gastroenterology 2008). The inflammation-modulation literature is concentrated in murine models of colitis and intestinal inflammation, with some work extending to skin inflammation contexts.
The mechanistic pathways are entirely unrelated. TB-500 operates through cytoskeletal dynamics and cell-migration modulation. KPV operates through inflammatory-pathway inhibition at the NF-κB level. They share the broad regeneration-and-inflammation research space but have no mechanistic intersection in the published literature.
How research has examined each
The TB-500 / thymosin β4 literature spans cardiac repair (Bock-Marquette et al., Nature 2004), corneal wound healing (Sosne et al.), dermal regeneration (Kleinman and Sosne), and angiogenesis in critical limb ischemia models. The cardiac-repair line of work describes re-entry of quiescent epicardial cells into a migratory phenotype. The evidence base is mature, with studies spanning from the 1990s to the present.
The KPV literature is concentrated in inflammatory bowel disease models. Dalmasso et al. characterised PepT1-mediated uptake and NF-κB inhibition in intestinal epithelial cells. Kannengiesser et al. demonstrated effects in murine colitis models. Viennois et al. examined the tripeptide in colitis-associated cancer models. More recent work has investigated nanoparticle-based delivery systems (Xiao et al.) and hydrogel formulations (Sun et al.) for targeted intestinal delivery.
The two literatures do not cite one another in primary research. Where overlap appears is in survey reviews of peptide-based inflammation and regeneration research that list both compounds alongside other regenerative and anti-inflammatory peptides. A researcher reading both is reading two separate research traditions with different lead authors, journals, and model systems.
Stacking considerations in research contexts
Combined administration of TB-500 and KPV is not described in the published literature. The mechanisms are unrelated (actin-cytoskeleton modulation versus NF-κB inhibition), so no direct pharmacological collision is anticipated, but no published protocol describes the combination. Both compounds are supplied as separate 10 mg lyophilised vials in the Ronin catalog for independent sourcing.
Sourcing both at Ronin
Both compounds in the Ronin catalog ship as 10 mg lyophilised peptide in glass vials, capped and crimped, with certificate-of-analysis documentation (mass spec + HPLC purity) on the lab-results page. The TB-500 vial page and the KPV vial page carry per-compound spec sheets, reconstitution math, and storage guidance. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.
Frequently asked research questions
Are TB-500 and KPV chemically related?
No. TB-500 is a 17-residue fragment of thymosin beta 4. KPV is a tripeptide (Lys-Pro-Val) derived from alpha-MSH. They share no sequence homology or precursor protein.
Do they target the same pathway?
No. TB-500 modulates actin-cytoskeleton dynamics and cell migration. KPV inhibits the NF-kappa-B inflammatory pathway. The mechanisms are unrelated.
Are they ever co-administered in research?
Not in the published literature. The mechanisms do not overlap, but no combined-protocol data exist.
Do they share storage practice?
Yes. Both are lyophilised peptides in glass vials, reconstituted in bacteriostatic water, and stored refrigerated at 2-8 degrees Celsius protected from light.
Are either approved for human use?
Neither is approved by the FDA or Health Canada as a human therapeutic. Both are sold strictly as research-grade reagents for laboratory applications.
References
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration and survival. Nature, 2004. [PMID 15565145]
- Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. [PMID 18061177]
- Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008. [PMID 18092346]
- Kleinman HK et al. Thymosin beta4 promotes dermal healing. Vitamins and Hormones, 2016. [PMID 27450738]
- Xiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy, 2017. [PMID 28143741]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.